title: Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.
abstract: The asbestos induced cancer malignant mesothelioma (MM) is difficult to diagnose and has a poor prognosis. MM is an immunological cancer, therefore autoantibodies may be suitable biomarkers and associated with prognosis. We used Protoarray(®) microarrays to determine immune responses to 8798 antigens in 10 MM and 10 asbestos exposed controls and developed diagnostic panels using 17 antigens from this. The AUC of these panels were independently tested in these 10 MM patients and controls and in a validation group of 36 controls and 35 MM patients using luminex assays; none of the antigens identified were validated. Immune responses to RAB38 were associated with a better prognosis.
authors.affiliation: a National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia , Perth , Western Australia , Australia ;|b Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital , Hospital Ave , Nedlands , Western Australia , Australia ;
authors.forename: Jenette
authors.initials: J
authors.lastname: Creaney
authors.affiliation: c National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital , Hospital Ave , Nedlands , Western Australia , Australia ;
authors.forename: Ian M
authors.initials: IM
authors.lastname: Dick
authors.affiliation: d Department of Respiratory Medicine , Sir Charles Gairdner Hospital , Hospital Ave , Nedlands , Western Australia , Australia ;|e National Centre for Asbestos Related Diseases, School of Population Health and School of Medicine and Pharmacology, University of Western Australia , Perth , Western Australia , Australia ;
authors.forename: A W Bill
authors.initials: AW
authors.lastname: Musk
authors.affiliation: f School of Population Health, University of Western Australia , Perth , Western Australia , Australia ;
authors.forename: Nola J
authors.initials: NJ
authors.lastname: Olsen
authors.affiliation: g National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia , Perth , Western Australia , Australia ;|h Department of Respiratory Medicine , Sir Charles Gairdner Hospital , Hospital Ave , Nedlands , Western Australia , Australia.
authors.forename: Bruce W S
authors.initials: BW
authors.lastname: Robinson
mesh_terms: D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood; D000951:Antigens, Neoplasm / Q000097:blood / Q000276:immunology; D001194:Asbestos / Q000633:toxicity; D001323:Autoantibodies / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D016022:Case-Control Studies; D004781:Environmental Exposure; D005260:Female; D063990:Gene Ontology; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D008875:Middle Aged; D058977:Molecular Sequence Annotation; D010997:Pleural Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D011379:Prognosis; D012189:Retrospective Studies; D020691:rab GTP-Binding Proteins / Q000276:immunology
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor; D001194:Asbestos; C412058:RAB38 protein, human; D020691:rab GTP-Binding Proteins
keywords: Biomarker; immunoreactivity; luminex; mesothelioma; protoarray